Company intelligence / Profile preview

Radion

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Company has 10 drug candidates and leads in preclinical development targeting various GPCR receptors for solid tumor treatment. No clinical trials initiated as of available information.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall molecule
Industry: Biotech

Partnerships

Eli Lilly: Option agreement for $1 billion acquisition, with $140 million upfront payment in 2024 (Acquisition option)Crinetics Pharmaceuticals: Research collaboration and exclusive worldwide license to radiotherapeutics technology platform (Licensing and collaboration)

Beyond the preview

Go deeper on Radion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radion.

Explore the full profile